Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Sohag University

Status: Completed

Conditions: Cancer of Colon

Treatments: Genetic: Immunohistochemistry

Study type: Observational

Funder types: Other

Identifiers

NCT05553080

Soh-Med-22-09-14

Details and patient eligibility

About

Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Full description

colorectal carcinoma is an aggressive malignant tumor. It has high incidence of cancer-related morbidity and mortality. the malignant potential of a given neoplasm is based mainly on its ability to invade the surrounding vasculature and reach to distant sites, the latter is called metastasis. in order to metastasize to distant sites, the neoplastic cells must re-arrange the intracellular actin filaments into well formed intracellular assembly which enable the neoplastic cells to reach to distant sites. Fascin-1 is an actin binding protein, it is involved in reconstruction of actin assembly. fortunately, Fascin-1 could be blocked by newly developed medications, blocking of Fascin-1 may limit the metastasis of colorectal carcinoma. in current study the investigators detect Fascin-1 in colorectal carcinoma by immunohistochemical approach, then they correlated different levels of Fascin-1 expression to tumor clinical and pathological criteria as patients' ages, sexes, tumor stages, nodal metastasis, vascular and per-ineural invasions.

Enrollment: 60 patients

Sex: All

Ages: 30 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All cases of colorectal carcinoma.

Exclusion criteria

• cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy.
• Patients with preopoerative history of chemo or radiotherapy.
• Patients with poor clinical data.